MicroRNA-9 Enhances Chemotherapy Sensitivity of Glioma to TMZ by Suppressing TOPO II Via the NF-κB Signaling Pathway

Overview

Journal Oncol Lett

Specialty Oncology

Date 2019 Jun 13

PMID 31186688

Citations 6

Authors

Qingla Li

Yingnan Chang

Luyan Mu

Yuwen Song

Affiliations

Soon will be listed here.

Abstract

Glioma is the most common primary tumor of the central nervous system (CNS) that develops chemotherapy resistance. The microRNA (miRNA) miR-9 is a tissue-specific miRNA of the CNS that may serve a key role in the modulation of chemotherapy sensitivity. The aim of the present study was to investigate the effect of miR-9 on glioma chemotherapy sensitivity by altering the expression of miR-9 in U251 glioma cells by viral transfection and subsequently treating with gradient concentrations of temozolomide (TMZ). Cell viability, apoptosis and the cell cycle were examined, and drug resistance genes were analyzed by western blotting. The role of nuclear factor κB (NF-κB) in this regulation was also examined. The results revealed that the susceptibility of glioma cells to TMZ was enhanced by miR-9 overexpression. When miR-9 and TMZ were applied together, the apoptotic rate and percentage of cells arrested at the G2/M stage were significantly higher compared with either treatment alone. Topoisomerase II expression was suppressed by miR-9 via the NF-κB signaling pathway, which may be responsible for the sensitization. The results of the present study suggested that miR-9 may be a potential target for glioma chemotherapy.

Citing Articles

Role of Non-coding RNAs in the Response of Glioblastoma to Temozolomide.

Goleij P, Pourali G, Raisi A, Ravaei F, Golestan S, Abed A Mol Neurobiol. 2024; 62(2):1726-1755.

PMID: 39023794 DOI: 10.1007/s12035-024-04316-z.

Nikolova E, Laleva L, Milev M, Spiriev T, Stoyanov S, Ferdinandov D Noncoding RNA Res. 2023; 9(1):141-152.

PMID: 38035044 PMC: 10686814. DOI: 10.1016/j.ncrna.2023.10.003.

RUNX1 (RUNX family transcription factor 1), a target of microRNA miR-128-3p, promotes temozolomide resistance in glioblastoma multiform by upregulating multidrug resistance-associated protein 1 (MRP1).

Xu J, Song J, Xiao M, Wang C, Zhang Q, Yuan X Bioengineered. 2021; 12(2):11768-11781.

PMID: 34895074 PMC: 8810036. DOI: 10.1080/21655979.2021.2009976.

MiR-9-1 Suppresses Cell Proliferation and Promotes Apoptosis by Targeting UHRF1 in Lung Cancer.

Jia C, Xiang W, Liu J, Jiang G, Sun F, Wu J Technol Cancer Res Treat. 2021; 20:15330338211041191.

PMID: 34520284 PMC: 8445543. DOI: 10.1177/15330338211041191.

Roles of the SNHG7/microRNA‑9‑5p/DPP4 ceRNA network in the growth and I resistance of thyroid carcinoma cells through PI3K/Akt activation.

Chen W, Yu J, Xie R, Zhou T, Xiong C, Zhang S Oncol Rep. 2021; 45(4).

PMID: 33649840 PMC: 7877006. DOI: 10.3892/or.2021.7954.

References

Boland M, Fitzgerald K, ONeill L . Topoisomerase II is required for mitoxantrone to signal nuclear factor kappa B activation in HL60 cells. J Biol Chem. 2000; 275(33):25231-8. DOI: 10.1074/jbc.275.33.25231. View

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, De Vitis S . Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res. 2004; 64(19):7011-21. DOI: 10.1158/0008-5472.CAN-04-1364. View

Krichevsky A, Sonntag K, Isacson O, Kosik K . Specific microRNAs modulate embryonic stem cell-derived neurogenesis. Stem Cells. 2005; 24(4):857-64. PMC: 2605651. DOI: 10.1634/stemcells.2005-0441. View

Hermisson M, Klumpp A, Wick W, Wischhusen J, Nagel G, Roos W . O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells. J Neurochem. 2006; 96(3):766-76. DOI: 10.1111/j.1471-4159.2005.03583.x. View

Roos W, Batista L, Naumann S, Wick W, Weller M, Menck C . Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine. Oncogene. 2006; 26(2):186-97. DOI: 10.1038/sj.onc.1209785. View

Laios A, OToole S, Flavin R, Martin C, Kelly L, Ring M . Potential role of miR-9 and miR-223 in recurrent ovarian cancer. Mol Cancer. 2008; 7:35. PMC: 2383925. DOI: 10.1186/1476-4598-7-35. View

Omura N, Li C, Li A, Hong S, Walter K, Jimeno A . Genome-wide profiling of methylated promoters in pancreatic adenocarcinoma. Cancer Biol Ther. 2008; 7(7):1146-56. PMC: 2763640. DOI: 10.4161/cbt.7.7.6208. View

Nass D, Rosenwald S, Meiri E, Gilad S, Tabibian-Keissar H, Schlosberg A . MiR-92b and miR-9/9* are specifically expressed in brain primary tumors and can be used to differentiate primary from metastatic brain tumors. Brain Pathol. 2008; 19(3):375-83. PMC: 2728890. DOI: 10.1111/j.1750-3639.2008.00184.x. View

10.

Shibata M, Kurokawa D, Nakao H, Ohmura T, Aizawa S . MicroRNA-9 modulates Cajal-Retzius cell differentiation by suppressing Foxg1 expression in mouse medial pallium. J Neurosci. 2008; 28(41):10415-21. PMC: 6671033. DOI: 10.1523/JNEUROSCI.3219-08.2008. View

11.

Nitiss J . Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer. 2009; 9(5):338-50. PMC: 2748742. DOI: 10.1038/nrc2607. View

12.

Iorio M, Croce C . MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol. 2009; 27(34):5848-56. PMC: 2793003. DOI: 10.1200/JCO.2009.24.0317. View

13.

Myatt S, Wang J, Monteiro L, Christian M, Ho K, Fusi L . Definition of microRNAs that repress expression of the tumor suppressor gene FOXO1 in endometrial cancer. Cancer Res. 2009; 70(1):367-77. PMC: 2880714. DOI: 10.1158/0008-5472.CAN-09-1891. View

14.

Wan H, Guo L, Liu T, Liu M, Li X, Tang H . Regulation of the transcription factor NF-kappaB1 by microRNA-9 in human gastric adenocarcinoma. Mol Cancer. 2010; 9:16. PMC: 2835654. DOI: 10.1186/1476-4598-9-16. View

15.

Hildebrandt M, Gu J, Lin J, Ye Y, Tan W, Tamboli P . Hsa-miR-9 methylation status is associated with cancer development and metastatic recurrence in patients with clear cell renal cell carcinoma. Oncogene. 2010; 29(42):5724-8. DOI: 10.1038/onc.2010.305. View

16.

Bonev B, Pisco A, Papalopulu N . MicroRNA-9 reveals regional diversity of neural progenitors along the anterior-posterior axis. Dev Cell. 2011; 20(1):19-32. PMC: 3361082. DOI: 10.1016/j.devcel.2010.11.018. View

17.

Otaegi G, Pollock A, Hong J, Sun T . MicroRNA miR-9 modifies motor neuron columns by a tuning regulation of FoxP1 levels in developing spinal cords. J Neurosci. 2011; 31(3):809-18. PMC: 3040495. DOI: 10.1523/JNEUROSCI.4330-10.2011. View

18.

Wang J, Gu Z, Ni P, Qiao Y, Chen C, Liu X . NF-kappaB P50/P65 hetero-dimer mediates differential regulation of CD166/ALCAM expression via interaction with micoRNA-9 after serum deprivation, providing evidence for a novel negative auto-regulatory loop. Nucleic Acids Res. 2011; 39(15):6440-55. PMC: 3159468. DOI: 10.1093/nar/gkr302. View

19.

Schraivogel D, Weinmann L, Beier D, Tabatabai G, Eichner A, Zhu J . CAMTA1 is a novel tumour suppressor regulated by miR-9/9* in glioblastoma stem cells. EMBO J. 2011; 30(20):4309-22. PMC: 3199389. DOI: 10.1038/emboj.2011.301. View

20.

Arivazhagan A, Kumar D, Sagar V, Patric I, Sridevi S, Thota B . Higher topoisomerase 2 alpha gene transcript levels predict better prognosis in GBM patients receiving temozolomide chemotherapy: identification of temozolomide as a TOP2A inhibitor. J Neurooncol. 2011; 107(2):289-97. DOI: 10.1007/s11060-011-0758-3. View